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Blood pressure (BP) is hardly controlled in chronic kidney
disease (CKD). We compared the effect of very low protein
diet (VLPD) supplemented with ketoanalogs of essential
amino acids (0.35 g/kg/day), low protein diet (LPD, 0.60 g/kg/
day), and free diet (FD) on BP in patients with CKD stages 4
and 5. Vegetable proteins were higher in VLPD (66%) than in
LPD (48%). LPD was prescribed to 110 consecutive patients;
after run-in, they were invited to start VLPD. Thirty subjects
accepted; 57 decided to continue LPD; 23 refused either
diet (FD group). At baseline, protein intake (g/kg/day) was
0.7970.09 in VLPD, 0.7870.11 in LPD, and 1.1170.18 in
FD (Po0.0001). After 6 months, protein intake was lower
in VLPD than LPD and FD (0.5470.11, 0.7870.10, and
1.0470.21 g/kg/day, respectively; Po0.0001). BP diminished
only in VLPD, from 143719/84710 to 128716/7877 mm
Hg (Po0.0001), despite reduction of antihypertensive drugs
(from 2.671.1 to 1.871.2; Po0.001). Urinary urea excretion
directly correlated with urinary sodium excretion, which
diminished in VLPD (from 181732 to 131736 mEq/day;
Po0.001). At multiple regression analysis (R2¼ 0.270,
Po0.0001), BP results independently related to urinary
sodium excretion (P¼ 0.023) and VLPD prescription
(P¼ 0.003), but not to the level of protein intake. Thus, in
moderate to advanced CKD, VLPD has an antihypertensive
effect likely due to reduction of salt intake, type of proteins,
and ketoanalogs supplementation, independent of actual
protein intake.
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Elevated blood pressure (BP) is the most frequent complica-
tion of chronic kidney disease (CKD).1 Its correction is a
prominent intervention because uncontrolled hypertension is
a recognized determinant of progression of renal damage;2–5
it also represents a major cause for the elevated cardio-
vascular morbidity and mortality detected in these patients.6–9
Accordingly, current clinical practice guidelines strongly suggest
reducing BP to less than 130/80 mm Hg.10
The achievement of BP goal in CKD in the ‘real world’ of
clinical practice, however, remains dramatically low even in
the presence of multidrug antihypertensive therapy including
inhibitors of renin-angiotensin system.1,11 This likely occurs
because in CKD patients hypertension is mainly related to the
impaired ability of the kidney to appropriately excrete dietary
salt.1,5 The consequent sodium retention, which is enhanced
by pharmacological treatment with vasodilator agents, defi-
nitely precludes an optimal control of BP.5 On the other
hand, short-term studies have shown that the sole dietary
restriction of salt, that is, in the absence of changes of protein
intake, markedly diminishes BP in patients with moderate to
advanced CKD.12,13 This non-pharmacological intervention,
moreover, enhances the antihypertensive and antiproteinuric
effect of renin-angiotensin system inhibitors.14,15
Unfortunately, the implementation of low sodium diet
in nephrology clinics is very low.1 This critical problem can
be explained by the observation that moderate protein
restriction, that is, the most frequent non-pharmacological
intervention in these patients, is not coupled with a signi-
ficant reduction of salt intake.1,16 However, the effect on
dietary sodium intake of a marked dietary restriction of
protein, such as that obtained by means of a supplemented
very low protein diet (VLPD), remains undefined. Indeed, in
well-motivated CKD patients, VLPD seems to be more
efficacious than standard low protein diet (LPD) in reducing
signs and symptoms of uremia, and postponing the need
of dialysis independent of the rate of glomerular filtration
rate (GFR) decline.17–19 Therefore, it is possible to hypo-
thesize that VLPD, besides reducing levels of urea, phosphate,
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and other uremic toxins, may also limit the intake of
salt,19 and, consequently, the degree of extracellular volume
expansion.
This hypothesis, even though extremely intriguing and
of great potential clinical impact, has never been verified
in CKD patients. To this aim, we assessed in hypertensive
patients with moderate to advanced CKD, the antihyper-
tensive effect of a VLPD supplemented with essential amino
acids and ketoanalogs, as compared with standard LPD and
unrestricted diet.
RESULTS
One hundred and fourteen patients were selected on the basis
of inclusion criteria. We excluded four patients because of
neoplastic disease (n¼ 3) or infectious disease (n¼ 1). At the
end of the run-in period of standard LPD, 27% of patients
chose the VLPD, whereas 52% of them preferred to remain at
LPD and 21% refused either diet (free diet (FD) group). The
main demographic and clinical characteristics of patients in
VLPD, LPD, and unrestricted FD groups were similar
(Table 1). Throughout the 6 months of follow-up, no patient
dropped off the study and none progressed toward end-stage
renal disease.
At baseline, the achievement of recommended target
(BPo130/80 mm Hg) was similarly poor in the three groups
(Table 2). The mean number of prescribed antihypertensive
drugs was generally greater than two. The most common
agents prescribed were angiotensin-converting enzyme inhi-
bitors and angiotensin II blockers; the distribution of the
main antihypertensive drugs (antagonists of renin-angio-
tensin system and diuretics) was similar in the three groups.
During follow-up, VLPD patients showed a significant
reduction of both systolic and diastolic BP values after
3 and 6 months and a consequent increase in the number
of patients reaching the BP target. Better BP control occurred
in the presence of a significant reduction of the number of
antihypertensive drugs. In contrast, BP control remained
unmodified in LPD and FD patients.
Variation of dietary intake of protein and salt and of
fractional urinary excretion of sodium (FENa), associated to
Table 1 | Basal characteristics of patients at VLPD, LPD,
and FD
VLPD LPD FD
N 30 57 23
Age, years 58.0716.1 56.3715.7 56.3715.6
Male gender, n (%) 18 (60) 29 (51) 14 (61)
BMI, kg/m2 23.972.5 25.574.3 24.272.4
CrCl, ml/min/1.73 m2 17.175.5 18.276.0 17.675.3
Renal Disease, %
Glomerulonephritis 33.3 33.3 21.7
Hypertensive nephropathy 16.7 14.0 17.4
Diabetic nephropathy 3.3 10.5 21.7
PKD 23.3 19.3 8.7
Other or unknown 23.3 22.8 30.4
BMI, body mass index; CrCl, 24 h-measured creatinine clearance; FD, free diet; LPD,
low protein diet; PKD, polycystic kidney disease; VLPD, very low protein diet.
Table 2 | Dietary protein and salt intakes and management of hypertension at baseline and during follow-up in patients at
VLPD, LPD, and FD
VLPD LPD FD
Baseline 3 months 6 months Baseline 3 months 6 months Baseline 3 months 6 months
PI, g/kg/day 0.7970.09 0.5770.19a,b 0.5470.11b,c 0.7870.11 0.7770.12 0.7870.10 1.1170.18 1.0670.18 1.0470.21
SI, mEq/day 181732 143738 131736b,c 170750 161757 166744 170760 175764 171751
SBP, mm Hg 143719 130717b 128716b,c 140721 138716 136715 141718 141719 139715
DBP, mm Hg 84710 8076 7877b,c 87710 8677 8677 8577 8475 8378
MBP, mm Hg 103711 9678a,b 9577a,b 105712 10378 10278 10479 10377 10278
BPo130/80, n (%) 2 (7) 4 (13) 9 (30)d 4 (7) 2 (3) 2 (3) 2 (9) 2 (9) 1 (4)
Drugs, n 2.671.1 1.771.1b 1.871.2b 2.071.1 1.871.2 2.171.3 2.171.2 1.771.2 2.071.1
Anti AII, n (%) 19 (63) 17 (57) 17 (57) 23 (40) 32 (56) 27 (47) 9 (39) 13 (56) 12 (52)
Diuretics, n (%) 15 (50) 16 (53) 18 (60) 24 (42) 26 (46) 29 (51) 10 (43) 9 (39) 11 (48)
FENa, (%) 8.674.0 7.175.1 6.273.4b 7.573.4 6.675.4 7.673.7 7.573.8 7.872.3 7.773.5
Anti AII, ACE-inhibitors and angiotensin II blockers; BP, blood pressure; DBP, diastolic blood pressure; Drugs, antihypertensive drugs; FD, free diet; FENa, fractional excretion of
sodium; LPD, low protein diet; MBP, mean blood pressure; PI, protein intake; SBP, systolic blood pressure; SI, sodium intake; VLPD, very low protein diet.
aPo0.001 vs baseline.
bPo0.0001 vs LPD and FD.
cPo0.01 vs LPD and FD.
dPo0.001 vs baseline and 3 months.
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Figure 1 | Percent changes of protein intake, salt intake, FENa
from baseline to 6 months, in patients at VLPD (white bars), LPD
(black bars), and FD (gray bars). *Po0.001 vs LPD and FD.
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BP changes, are depicted in Table 2 and Figure 1. At baseline,
the urinary urea excretion was similar in VLPD (6.571.5 g/
day) and LPD (6.271.3 g/day), whereas it was higher in FD
(9.471.5 g/day, Po0.001 vs other groups). During the study,
protein intake decreased in VLPD patients. This was coupled
with a significant reduction of both salt intake and FENa.
In contrast, no significant modification of these parameters
was observed in the other two groups. Indeed, the values
of urinary urea and sodium excretion at 6 months directly
correlated in VLPD patients (n¼ 30; R¼ 0.453, P¼ 0.012)
(Figure 2), whereas no correlation was found in LPD and FD.
No significant difference was detected in dietary compli-
ance between VLPD and LPD patients. Indeed, when consi-
dering acceptable a difference of less than 0.2 g/kg/day
between prescribed and achieved protein intakes, 77 and
63% of VLPD and LPD patients, respectively, adhered to the
diet at 6 months; similar results were obtained at 3 months
(data not shown). The analysis of dietary diaries revealed that
the sources of proteins exceeding prescription were mostly
represented by proteins of vegetable origin, such as pasta
and bread in both VLPD and LPD groups. In either LPD or
VLPD group, no patient had a protein intake lower than that
prescribed.
Changes of urinary sodium excretion did not differ
between diuretic-treated and diuretic-untreated patients
(20729 and 24725%, respectively, P¼ 0.744). Similarly,
the presence of polycystic kidney disease did not account
for the observed changes in urinary sodium excretion; in fact,
no significant difference in the changes of urinary sodium
excretion became apparent between patients with and with-
out polycystic kidney disease in either VLPD and LPD groups
(P¼ 0.208 and P¼ 0.534, respectively). Overall, no associa-
tion was found between renal disease and changes in sodium
excretion.
Modifications of renal function parameters and cardio-
renal risk factors during the study are reported in Table 3.
Creatinine clearance did not vary throughout follow-up in
either group. Only in VLPD patients, blood urea levels
markedly decreased in parallel with the reduction of urinary
urea excretion. Similarly, the urinary excretion of phosphate
decreased only in VLPD patients (from 6107226 to
3417182 mg/day at 6 months, Po0.0001), but not in LPD
and FD patients (data not shown). The mean values of
triglycerides and cholesterol decreased only in VLPD group;
calcium–phosphate product diminished exclusively in VLPD
patients, mainly because of the decrease of plasma levels of
phosphate (from 4.571.0 to 3.570.7 mg/dl at 6 months,
Po0.0001); similarly, parathyroid hormone (PTH) decreased
in VLPD, but not in LPD or FD group; also proteinuria
significantly diminished only in VLPD group. In contrast,
urinary excretion of potassium did not differ in the three
groups either at baseline or during the follow-up.
The different dietary regimens did not affect the nutri-
tional status; as reported in Table 3, in fact, body weight and
serum levels of albumin did not change; also transferrin
values and daily urinary creatinine excretion did not change
during the follow-up in any group of patients (data not
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Figure 2 | Relationship between values of 24-h urinary urea and
sodium excretion at 6 months in 30 patients at VLPD diet
(R¼ 0.453, P¼ 0.012).
Table 3 | Renal function and cardio-renal risk parameters at baseline and after 6 months in patients at VLPD, LPD, and FD
VLPD LPD FD
Baseline 6 months Baseline 6 months Baseline 6 months
Body weight, kg 67.5710.2 67.1711.0 67.8713.6 68.0713.9 65.177.3 65.677.3
GFR, ml/min/1.73 m2 17.175.5 17.876.6 18.276.0 17.777.0 17.675.3 16.175.8
Urea, mg/dl 146739 48719a,b 146748 145744 160737 165734
Albumin, g/dl 3.970.4 3.970.4 4.070.3 4.070.4 3.970.4 4.070.3
Hemoglobin, g/dl 11.670.8 11.570.8 11.671.2 11.670.9 11.571.2 11.371.0
TC, mg/dl 223736 169726a,b 216738 206736 214739 217736
TG, mg/dl 170740 140728a,b 176763 167737 170738 217736
CaxP, mg2/dl2 41710 3178b,c 3876 4075 3875 3975
PTH, pg/ml 1757115 109773a,d 1687114 1707108 190772 189782
UK, mEq/day 52717 51717 48713 48714 48714 49715
Proteinuria, g/day 1.3471.2 0.8770.8a 1.4371.55 1.2971.4 0.7970.9 0.8670.7
CaxP, calcium–phosphorus product; FD, free diet; GFR, 24-h measured creatinine clearance; LPD, low protein diet; PTH, parathyroid hormone; TC, total cholesterol;
TG, triglycerides; UK, urinary potassium excretion; VLPD, very low protein diet.
aPo0.0001 vs baseline.
bPo0.001 vs LPD and FD.
cPo0.001 vs baseline.
dPo0.01 vs LPD and FD.
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shown). Body weight was similar in diuretic-treated and
untreated patients in VLPD, LPD, and FD groups during the
study.
On the basis of these results, we carried out a multiple
regression analysis to determine the independent role of
the main clinical characteristics on achieved mean BP at
6 months (Table 4). The model, which explained 27% of
variance of mean BP, identified sodium intake (P¼ 0.023)
and prescription of supplemented VLPD (P¼ 0.003) as the
sole independent predictors of BP level at 6 months. Indeed,
the effects of age, gender, GFR, number of antihypertensive
drugs, use of diuretic, and protein intake were not significant.
DISCUSSION
This prospective study provides first-time evidence that in
patients with CKD stages 4 and 5, the VLPD supplemented
with ketoanalogs induces a marked and sustained decrease
of BP in the presence of reduction of prescribed antihyper-
tensive drugs. This effect was specifically related to the
prescription of VLPD, as standard LPD, similarly to the
unrestricted diet, was coupled with the maintenance of
higher BP levels. Such a peculiar benefit of VLPD was
observed in patients who started with inadequate BP control
at baseline in spite of multidrug antihypertensive therapy.
Specifically, after the 6-month period of follow-up, VLPD
helped in achieving BP target (o130/80 mm Hg) from 7 to
30% of patients and led to a sustained decrement in BP,
mainly owing to a large reduction, by 14 mm Hg on average,
in systolic BP. The maintenance of a similar reduction in
systolic BP is particularly relevant to prevent cardiovascular
events in high-risk patients, such as in the case of our
patients.20 In addition, adequate BP control in the pre-
dialysis phase of CKD effectively prevents cardiovascular
mortality during the subsequent dialysis period.21
A possible explanation to this beneficial effect of
VLPD derives from the contemporaneous examination of
salt intake and FENa (Figure 1). We observed a significant
decrement of these two parameters exclusively in VLPD
patients. The reduction of FENa, in the presence of stable
GFR and diminished sodium intake, indicates increased
tubular sodium reabsorption secondary to extracellular
volume contraction.5,12,13 It is, therefore, reasonable to hypo-
thesize that VLPD led to a reduction of volume expansion
secondary to the diminished salt intake. Indeed, in agreement
with the hypothesis of Guyton and Coleman on the salt
sensitivity of BP in essential hypertension,22 a positive salt
balance raises osmotic pressure, increases water intake, and
thus rapidly causes hypervolemia. The consequent increase of
peripheral vascular resistances, in turn, leads to the steady
hypertensive state. In CKD patients, the extracellular volume
expansion secondary to impaired sodium excretion occurs
since the early phase of the disease.23 Consequently, effective
correction of arterial hypertension is difficult to obtain in
these patients, even by multidrug therapy, if salt intake is
not restricted.5 Indeed, also efficacious decrement of sodium
intake is hard to achieve in CKD patients, as in non-CKD
hypertensive subjects.1,5 The present study evidences that
standard moderate protein restriction is not associated with
any beneficial effect on BP control with respect to unrest-
ricted protein diet. Although a parallel variation of protein
and salt intake during administration of restricted protein
diets has been previously hypothesized,19 no investigator has
ever formally addressed this issue. This study shows for the
first time that in CKD patients a direct relationship between
protein and sodium intake occurs during VLPD, but not
during LPD (Figure 2). Taken together, these data indicate
that extracellular volume expansion, which is a key deter-
minant of uremia-related hypertension,10,24–26 can be sub-
stantially corrected by means of severe protein restriction
because of the concomitant significant reduction of sodium
intake. Specifically, the estimation of NaCl content of low
protein products showed that VLPD provides almost 2 g/day
of NaCl less than LPD. Such an amount accounts for most of
the difference detected in urinary Na excretion during follow-
up between VLPD and LPD patients (Table 2).
The observed high extent of antihypertensive response to
moderate sodium restriction may be an unexpected finding.
As compared with CKD patients, in fact, in hypertensive
patients with normal GFR, a greater reduction of sodium
intake is associated with much lower decrements in systolic
and diastolic BP values.27,28 On the other hand, the anti-
hypertensive response to salt reduction, the so-called salt
sensitivity of BP, greatly increases in CKD in parallel with
worsening of renal function, because of the dependent
increment of the extracellular volume expansion.5,12,13,29
Therefore, in this study, a sustained decrease of sodium
intake of about 3 g NaCl/day secondary to the shift from LPD
to VLPD, was associated with a decrement of mean BP of
about 8–9 mm Hg; similarly, Koomans et al.13 found that in
advanced CKD a greater acute decrease of sodium intake of
about 6 g/day, in the absence of changes in protein intake, led
to a greater decrement of mean BP of about 12 mm Hg.
On the other hand, a previous study by our group indicates
that the isolated restriction of protein intake, that is, in the
presence of constantly normal salt intake, does not induce
any change of mean BP values in CKD patients.30 Overall,
Table 4 | Multiple regression analysis with mean BP at the
end of the study as dependent variable in stages 4 and 5 CKD
patients
b Coefficient P-value
Constant 94.817 0.0001
Age 0.075 0.119
Gender (female as reference) 0.302 0.845
eGFR 0.134 0.175
Number of antihypertensive drugs 1.256 0.101
Diuretic use 0.191 0.900
Protein intake 3.882 0.397
Supplemented VLPD 6.692 0.003
Sodium intake 0.696 0.023
BP, blood pressure; CKD, chronic kidney disease; eGFR, GFR estimated by
Cockroft–Gault equation; VLPD, very low protein diet.
Model summary: R2=0.270, P=0.0001.
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these data identify the moderate reduction of salt intake,
with the dependent partial correction of extracellular volume
expansion, as a relevant determinant of BP decrease during
VLPD. In addition, other authors have evidenced that
moderate dietary sodium restriction rapidly normalizes BP
in patients with systolic hypertension also by improving large
elastic artery compliance.31,32
According to the results of multivariate analysis (Table 4),
we can reasonably exclude that the variation of total protein
intake per se, as estimated by the daily urinary urea excretion,
can have an independent role in the reduction of BP. Protein
intake, as it was used for this analysis, is only a quantitative
parameter that does not distinguish the quality of proteins;
indeed, the ratio of vegetable to animal proteins was higher in
VLPD than in LPD. This observation is of interest as a
significant inverse relationship between intake of vegetable
proteins and BP levels has been documented.33 Thus, the
major portion of vegetable proteins in the VLPD may have
affected the BP. In addition, because of the significant effect
of VLPD prescription, we can hypothesize that the supple-
ment of ketoanalogs/amino acid in VLPD may also play a
direct role on BP control, possibly by inducing a vasodilator
effect through the increase of plasma concentrations of the
respective branched-chain essential amino acids.34,35
Other diet-related and -unrelated lifestyle modifications,
such as weight loss, increased potassium intake, reduction in
the plasma levels of cholesterol, phosphate, and PTH, might
lower BP.33,36,37 There are also some suggestions that
intensive cholesterol reduction by statin administration may
lower BP by improving artery stiffness and that pharmaco-
logical correction of calcium–phosphate metabolism and
secondary hyperparathyroidism may contribute to decreasing
BP in CKD.36,37 In our study, no change in body weight and
urinary potassium excretion was detected during follow-up.
Unlike this, we observed a significant reduction of plasma
cholesterol likely related to the lower content of cholesterol in
VLPD vs other diets; similarly, the lower intake of phosphate
in VLPD, as indicated by the lower urinary excretion, likely
accounted for the reduction of phosphatemia and the
consequent improvement of secondary hyperparathyroidism.
The therapeutic advantage of VLPD was not limited to the
better control of BP. During VLPD, in fact, we observed a
significant reduction in proteinuria, which is an independent
predictor of renal and cardiovascular outcome.38 The
antiproteinuric response to VLPD was likely related to the
amelioration of glomerular hypertension owing to the
lowering of systemic BP, and also to the reduction of protein
and salt intake per se, as suggested by different authors.38–41
Of note, according to Klosa et al.,42 a reduction of protein-
uria of at least 35% associated with a reduction in BP, as
observed in the present study, predicts a better renal and
cardiovascular prognosis over the long run.
A limitation of the study is represented by the non-
randomized assignment of different protein regimens; there-
fore, minor selection biases cannot be excluded. However,
the number of enrolled patients was sufficient to avoid any
significant difference in the main demographic and clinical
basal characteristics among the three groups. On the other
hand, the spontaneous clustering of patients in the three
groups allowed us to evaluate the rate of acceptance for
either diet; to our knowledge, this is the first study evaluating
the implementation of dietary protein restriction on single
patient-level basis. We found that the choice of LPD almost
doubled that of VLPD (52 vs 27%). Nonetheless, compared
to LPD, in VLPD patients the adherence to the diet was not
reduced; indeed, almost two-third of patients were compliant
to the diet in either group. These findings overall indicate
that intensive protein restriction represents a major change in
lifestyle and is accepted by only a minority of CKD patients,
even when they are greatly motivated because renal function
is close to the pre-dialysis value; however, once accepted by
the patient, compliance to this diet is quite high.
In conclusion, this prospective study represents the
first evidence that in moderate to advanced CKD, the VLPD
diet supplemented with ketoanalogs, as compared to
either standard LPD or unrestricted diet, allows a marked
and sustained improvement of BP control which is associated
with a significant decrement in the extent of proteinuria.
This beneficial effect, rather than being dependent on the
effective amount of ingested proteins, appears to be directly
dependent to the specific characteristics of the VLPD (type
of proteins, cholesterol, and phosphate content), and also to
ketoanalog supplementation, as well as to the concomitant
reduction of salt intake with consequent partial correction of
extracellular volume expansion.
These findings support the daily efforts of nephrologists in
challenging the reluctance of CKD patients to change their
lifestyle, especially when considering the elevated cardiovas-
cular risk associated with renal disease.
MATERIALS AND METHODS
Subjects
The study was performed in three outpatient nephrology clinics.
Consecutive incident CKD patients in the period 1 January to 31
December 2004 were enrolled according to the following inclusion
criteria: age X18 years, measured creatinine clearance less than
30 ml/min/1.73 m2, and arterial hypertension, defined as either use
of antihypertensive drugs or BP greater than 130/80 mm Hg in the
absence of antihypertensive drugs. Exclusion criteria were preg-
nancy, history of dialysis/renal transplantation, malignant disease,
infectious disease, use of immunosuppressive drugs, and acute
changes of renal function.
Design of the study
The study was a prospective, controlled study. A 3-month period of
run-in preceded the study; during this period, all new CKD stages 4
and 5 patients who met the inclusion criteria were prescribed a
standard LPD (0.60 g protein/kg body weight/day). In each patient,
we verified the stability of creatinine clearance measured in three
separate visits (coefficient of variation o5%), and the nutritional
and metabolic status. After run-in was completed, we proposed to
all patients the supplemented VLPD (0.30 g of protein/kg body
weight/day). Patients refusing VLPD were invited to remain on their
standard LPD. If also this latter choice was not accepted, the patient
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was included in the FD group. All patients were prescribed at least
30 kcal/kg/day of energy; a lower intake of calories was considered in
those with body mass index 430 kg/m2. VLPD diet was supple-
mented with a mixture of ketoanalogs and essential amino acids
(Alfa Kappa; Shire Italia, Firenze, Italy) administered at the dose of
one pill per 5 kg body weight, in order to maintain the neutral
nitrogen balance even at the lower protein intakes, thus to increase
the efficiency of nitrogen utilization and to maintain a good
nutritional status.43 Each pill contained calcium keto-isoleucine
67 mg, calcium keto-leucine 101 mg, calcium keto-alanine 68 mg,
calcium keto-valine 86 mg, calcium hydroxyl-methionine 59 mg,
L-lysine monoacetate 105 mg, L-threonine 53 mg, L-histidine 38 mg,
and L-tyrosine 30 mg. Inclusion of the amino acids by the oral
supplements as an additional source of nitrogen, resulted in a mean
total protein prescription (from food and supplements) of 0.35 g/kg/
day in the VLPD group. The content of cholesterol in the VLPD and
LPD diets was 60–80 and 90–130 mg/day, respectively. The two diets
had the same content of NaCl (less than 1 g/day) when considering
fresh food shared by the two diets, that is, milk, meat, fish, fresh
cheese, and vegetables/fruit; whereas NaCl content differed when
examining bakery products (bread and analogs) and pasta.
Specifically, owing to both the difference in sodium content between
protein and no-protein pasta, and bakery products and the
difference in the amount of such food between the two diets, the
daily salt amount was almost 2 g higher in LPD vs VLPD (i.e. in the
diet containing 1900 kcal, which was the most frequently prescribed,
the whole sodium content was 1260 mg/day (53 mEq¼ 3.1 g NaCl)
and 540 mg/day (22 mEq¼ 1.3 g NaCl), respectively, in LPD and
VLPD diets). All patients at the first visit received the common
indications to minimize added salt in order to keep daily sodium
intake o100 mmol. As a further difference, the two diets contained
a different percentage of vegetable proteins that was equal to 48% in
LPD and 66% in VLPD, respectively.
Antihypertensive therapy was prescribed to all patients during
the run-in period to obtain the BP target of levelso130/80 mm Hg;
it included angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers, calcium channel blockers, diuretics (oral furose-
mide at the daily dose of 50 mg in patients with GFR ranging from
30 to 15 ml/min/1.73 m2, and 75 mg in patients with GFR lower than
15 ml/min/1.73 m2), b-blockers, or a-blockers. During the study, the
number of antihypertensive drugs was reduced if systolic BP reached
values o115 mm Hg or in the presence of symptomatic hypo-
tension. Changes in the number of antihypertensive drugs were
made after examining the clinical and laboratory data.
During the run-in, patients were trained to correctly collect the
24-h urine. Patients underwent a complete study including blood
withdrawal and urine collection, at baseline and after 3 and 6 months.
They underwent a clinical evaluation every month, including the
measurement of body weight and BP, with eventual adjustment of
therapy, and the dietetic counseling by a skilled dietician including
evaluation of the adherence to the prescribed diet. There was at least
1 month period between change of therapy and laboratory determi-
nations to allow the achievement of steady state for sodium balance
and to avoid changes of sodium excretion eventually related to change
in diuretic prescription. Patients ended the observation if creatinine
clearance decreased to less than 7 ml/min/1.73 m2 or in the case of
development of uremic complications requiring dialysis treatment.44
Measurements and calculations
During the physician’s visit (0800–1000 h), clinical BP was measured,
according to the recommendations of the European Society of
Hypertension,45 in a quiet environment with a mercury sphygmo-
manometer with the patient in a sitting position after 5 min of
rest. Systolic and diastolic BP values (Korotkoff phases I and V,
respectively) represented in each visit the mean of three different
readings measured at 5-min intervals. In each patient, measure-
ments were obtained by the same physician during the whole study.
Measurements of clinical BP were performed on the morning just
before the administration of drug(s). Mean BP was calculated by
using the formula (2 diastolic pressure)þ systolic pressure/3.
Body mass index was calculated as body weight (kg)/square value
of the height (m).
At each time point of the study, we measured in blood samples
urea, creatinine, sodium, potassium, phosphate, calcium, intact
PTH, total proteins, albumin, total cholesterol, triglycerides, trans-
ferrin, and hemoglobin. In the 24-h urinary collection, we measured
the excretion of urea, creatinine, sodium, potassium, phosphate, and
proteins; the daily urine collection was considered inaccurate and
discarded if the value of measured creatinine excretion was outside
the 60–140% range of the value calculated according to Dwyer and
Kenler.46 The FENa was calculated as 24-h urinary excretion of
sodium (urinary concentration of sodium (mEq/l) urinary output
(ml/24 h)) 100/(GFR (ml/24 h) plasma sodium concentration
(mEq/l)).
Serum albumin, serum and urinary levels of creatinine, urea,
sodium, phosphate and potassium were measured by autoanalyzer
(Olympus AU 400; Olympus Italia, Segrate, Italy). Measurement of
proteinuria was performed by pyrogallol red-molibdate method.
Creatinine in plasma and urine was measured by means of modified
kinetic Jaffe` reaction. Hemoglobin was measured by Coulter counter
(Coulter Electric, Hialeah, FL, USA). PTH level was assessed by
standard radioimmunoassay method using two affinity-purified
goat antibodies specific for two different regions of the PTH
molecule (PTH 1–34 and PTH 39–84) (Sorin, Saluggia, Italy).
Daily salt intake in grams per day was calculated dividing the
24-h urinary sodium excretion by 17.1.10,12,27 Dietary protein intake
was estimated from the 24-h urea nitrogen excretion according to
Maroni et al.47
Statistical analysis
Continuous variables were expressed as mean7s.d. and compared
with analysis of variance except for variables with non-normal
distribution (identified by Shapiro–Wilk test) that was analyzed
with Kruskall–Wallis test. The changes of continuous variables
during the follow-up (intra-group comparisons) were assessed by
means analysis of variance for repeated measurements or by
Friedman’s test for those with non-normal distribution. Categorical
variables were expressed as percentage and compared by using
w2 test. Linear correlation analysis and multiple regression analysis
were also used; the latter was applied to evaluate the relationships
between achieved mean BP and main clinical variables, considering
age, antihypertensive drugs, protein intake, sodium intake, and
estimated GFR as continuous variables, and gender, supplemented
VLPD, and diuretic treatment as categorical variables. A two-tail
P-value o0.05 was considered statistically significant.
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